Skip to main content
2885 search results for:

Triptan Drugs 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | OriginalPaper

    Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events

    Sumatriptan and the other second-generation serotonin 5HT1B/1D-receptor agonists (triptans) have improved the quality of life of migrainers by providing a higher degree of efficacy and a more favorable safety profile, in comparison with …

  2. Open Access 01-12-2024 | Migraine | OriginalPaper

    Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis

    Migraine is a common neurological disorder that is commonly comorbid with a range of conditions and diseases, including depression, anxiety, chronic pain, and epilepsy [ 1 ]. It affects more than 1 billion people worldwide [ 2 ]. China is a country …

  3. Open Access 16-04-2024 | Migraine | Online First

    Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational Study

    Migraine is a debilitating neurological condition with an overall prevalence of approximately 15% in Europe [ 1 ], and 1-year prevalences of 12.6% in Spain [ 2 ] and 16.6% in Germany [ 3 ]. Reported prevalence estimates vary between studies …

  4. Open Access 27-03-2024 | Triptan Drugs | Online First

    Acute treatment of migraine: quantifying the unmet need through real-world data in Italy

    Migraine is a common neurological disorder whose onset is usually in adolescence or early adult life [ 1 ] and presents with symptoms which affect people’s quality of life limiting their participation in work, family, and social activities [ 2 ].

  5. 16-02-2024 | Triptan Drugs | News | Article

    Triptan-associated ischemic events linked to high background CV risk 

    Triptan use for migraines may be associated with a small short-term increased risk for myocardial infarction and ischemic stroke, but this primarily occurs in patients with high a cardiovascular risk profile.

  6. 08-03-2024 | Erenumab | ReviewPaper

    Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions

    Calcitonin gene-related peptide neurotransmission was the target for recent development of monoclonal antibodies that effectively prevent attacks of both episodic and chronic migraine. The aim of this narrative review was to offer deeper insight …

  7. Open Access 01-12-2024 | Migraine | OriginalPaper

    Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

    Migraine is a debilitating primary headache disorder, negatively affecting both daily functioning and health-related quality of life. Globally, migraine is the second most common cause of disability among women aged 15 to 49 years, according to …

  8. Open Access 06-03-2024 | Migraine | Review

    Acute migraine: is there still a role for conventional therapy?

    In early treatment of acute migraine pain, combined paracetamol and caffeine can benefit pediatric or older patients and those with cardiovascular comorbidities, pregnancy or breastfeeding, or poor response to trigeminal targeted therapies.

  9. 06-04-2024 | Triptan Drugs | Online First

    Triptans in the Acute Migraine Management of Children and Adolescents: An Update

    Pediatric migraine is a common neurological condition with evidence of an increasing burden over the last several years [ 1 – 5 ]. An estimated 11% of children have migraine headaches. The prevalence increases with age, peaking at up to 25% for …

  10. Open Access 19-01-2024 | Migraine | OriginalPaper

    Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)

    Migraine is a neurological disorder that causes recurrent and episodic moderate-to-severe headaches [ 1 ]. Given its high global prevalence and debilitating effects, the adverse impact of migraine on patients’ quality of life (QoL) cannot be …

  11. Open Access 01-12-2024 | Migraine | OriginalPaper

    Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan

    Migraine is the most common multifactorial neurologic disorder which has remained as one of the prominent causes affecting patients’ quality of life and daily functions [ 1 ]. It is characterized by incidences of relapse and remittance of extreme …

  12. Open Access 01-12-2024 | Medication Overuse Headache | OriginalPaper

    Unsatisfactory response to acute medications does not affect the medication overuse headache development in pediatric chronic migraine

    Migraine is the primary cause of pain in childhood and its frequency increases with age, overtaking 20% in adolescence [ 1 ]. Throughout life, the frequency, severity, and disability of this condition can fluctuate. The transition between episodic …

  13. 01-10-2014 | News

    Antiepileptic drugs/granisetron/oxitriptan

    Somnolence, serotonin syndrome, worsening post-anoxic myoclonus (first report with granisetron), and diarrhoea: 2 case reports
  14. Open Access 01-12-2024 | Migraine | OriginalPaper

    Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain

    Migraine is a debilitating condition affecting over 14% of the global population [ 1 ]. It is the second leading cause of disability and the first among women aged between 15 and 49 years old [ 2 ]. The condition is typically classified as either …

  15. Open Access 17-01-2024 | Migraine | OriginalPaper

    Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

    Migraine is a chronic evolutive neurological disorder that is often under-estimated and under-treated [ 1 , 2 ]. Early and appropriate treatment for migraine is recommended not only to improve patients’ quality of life but also to prevent disease …

  16. 25-03-2024 | Migraine | Online First

    Migraine and gasdermin D: a new perspective on the inflammatory basis of migraine

    Migraine is a common and disabling primary headache disorder and inflammation is a proposed factor in the complex ethiology of the disease. Gasdermin D (GSDMD) is a membrane pore-forming protein acting through the caspase system. End result is …

  17. 02-04-2024 | Medication Overuse Headache | Online First

    The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial

    Migraine is a common, chronic disabling neurological disorder that is typically characterized by recurrent attacks of headache and accompanying symptoms, including aura [ 1 , 2 ]. According to the Global Burden of Diseases, Injuries, and Risk …

  18. Open Access 28-03-2024 | Galcanezumab | Online First

    Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study

    Migraine is a neurologic disease described by the International Classification of Headache Disorders (ICHD-II) as a recurrent headache disorder manifesting in attacks lasting 4–72 h without treatment and with typical characteristics, such as …

  19. 18-03-2024 | Cluster Headache | Online First

    Oxygen as an abortive therapy in cluster headache: a narrative review and clinical practice aspects

    Cluster headache (International Classification of Headache Disorders third edition, ICHD-3 3.1) is a primary headache disorder affecting around 0.12% of individuals. It is characterized by severe headache attacks causing significant negative …

  20. Open Access 01-03-2024 | Fremanezumab | OriginalPaper

    The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness

    Migraine is one of the most prevalent causes of disability worldwide [ 1 , 2 ]. Due to an impaired ability to perform daily activities, negative impacts on family life, loss of work productivity, reduced educational and career potential, and high …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.